Search

The accurate identification of drug-target affinity (DTA) is crucial for advancements in drug discovery and development. Many deep learning-based approaches have been devised to predict drug-target binding affinity accurately, exhibiting notable improvements in performance. However, the existing prediction methods often fall short of capturing the global features of proteins. In this study, we proposed a novel model called ETransDTA, specifically designed for predicting drug-target binding affinity. ETransDTA combines convolutional layers and transformer, allowing for the simultaneous extraction of both global and local features of target proteins. Additionally, we have integrated a new graph pooling mechanism into the topology adaptive graph convolutional network (TAGCN) to enhance its capacity for learning feature representations of chemical compounds. The proposed ETransDTA model has been evaluated using the Davis and Kinase Inhibitor BioActivity (KIBA) datasets, consistently outperforming other baseline methods. The evaluation results on the KIBA dataset reveal that our model achieves the lowest mean square error (MSE) of 0.125, representing a 0.6% reduction compared to the lowest-performing baseline method. Furthermore, the incorporation of queries, keys and values produced by the stacked convolutional neural network (CNN) enables our model to better integrate the local and global context of protein representation, leading to further improvements in the accuracy of DTA prediction. [ABSTRACT FROM AUTHOR]